For Biosimilars, A Mid-Review Cycle Product Quality Discussion Appears To Be A Bad Omen

 
• By Derrick Gingery
  
scientist working with vat in lab
The report also indicated BPD Type IV meetings were valuable to biosimilar sponsors. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics